Paragon 28 Announces Financial Reporting Schedule
Paragon 28, Inc. (NYSE: FNA), a notable entity in the medical device industry, has made headlines as it prepares to disclose its financial results for the third quarter of 2024. This announcement comes with great anticipation from investors and stakeholders alike, looking to gauge the company’s performance in the ever-evolving foot and ankle orthopedic market.
Event Details for Financial Results Report
The financial results will be revealed after the market closes on November 12, 2024, a strategic timing that allows investors to process the information without the rush typically associated with market hours. Following the announcement, Paragon 28 will host a conference call at 4:30 p.m. Eastern Time. This session allows investors to listen in and gain insights directly from the company’s management, offering a glimpse into future strategies.
How to Access the Conference Call
Investors can join the call by dialing (833-470-1428) for domestic inquiries, and (404-975-4839) for those calling internationally. To streamline the process, a conference ID of 725499 will be used. For those unable to attend live, a recorded archive of the webcast will be accessible on the “Investors” section of the Paragon 28 website for a minimum of 90 days.
Company Overview and Commitment to Innovation
Paragon 28 primarily focuses on providing state-of-the-art medical devices targeted at foot and ankle conditions. With its headquarters nestled in Englewood, Colorado, the company has established itself as a leading force in the orthopedic sector. Paragon 28's mission revolves around enhancing patient care through innovative orthopedic solutions, procedural methodologies, and specialized instrumentation.
Wide Range of Products and Solutions
The array of products offered by Paragon 28 spans a variety of foot and ankle issues. Their technological advancements cater to fracture fixation, forefoot and ankle treatments, as well as addressing complex conditions such as progressive collapsing foot deformity (PCFD), charcot foot, and orthobiologics. Each product is meticulously designed keeping the needs of both the patient and surgeon in mind.
Dedicated to Improving Patient Lives
Paragon 28 emphasizes the importance of patient outcomes and seeks to minimize ailment recurrence and complications. Their focus lies in crafting procedures that are not only simpler but also consistent and replicable. This commitment to innovation reflects Paragon 28’s vision to lead the orthopedic market with advancements that truly improve lives.
Looking Ahead
As the date for the financial results approaches, excitement brews around what new information will be shared and how it will shape the future of Paragon 28. Investors and interested parties are encouraged to stay engaged, as the outcomes discussed during the conference call could have significant implications for the company’s progress and growth within the orthopedic field.
Frequently Asked Questions
When will Paragon 28 announce its Q3 2024 financial results?
Paragon 28 is set to report its Q3 2024 financial results on November 12, 2024.
What time is the conference call scheduled?
The conference call will take place at 4:30 p.m. Eastern Time on the same day.
How can investors access the conference call?
Investors can dial (833-470-1428) for domestic calls or (404-975-4839) for international calls, using conference ID 725499.
Will the webcast be available for replay?
Yes, the webcast will be archived and accessible for at least 90 days after the event.
What is the main focus of Paragon 28?
Paragon 28 is dedicated to developing innovative solutions specifically for the foot and ankle orthopedic market, aimed at improving patient outcomes.
